Dr. Xiwen Fan 樊喜文
Chief Physician
Department of Interventional Therapy, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Interventional comprehensive treatment for various benign and malignant tumors.
Dr. Fan holds a Master of Medicine and has worked since November 1998. Graduating from Xinjiang Medical University in 2006, Dr. Fan serves as Deputy Director of the Interventional Diagnosis and Treatment Department at the Affiliated Cancer Hospital. Dr. Fan has led or participated in three regional science projects, published over 20 academic and SCI papers, and authored three books.
Professional roles
- Vice Chair, Tumor Intervention Professional Committee, Xinjiang Anti-Cancer Association
- Chair, Youth Committee, Tumor Intervention Professional Committee, Xinjiang Anti-Cancer Association
- Youth Member, Tumor Intervention Therapy Committee, China Anti-Cancer Association
- Youth Member, Liver Cancer Treatment Committee, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Fan Xiwen). Papers usually list the name as Xiwen Fan or Fan X.
Selected publications
6 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- Phytother Res, 2026 (first author): Dehydrocostus Lactone Suppresses Hepatocellular Carcinoma by Inhibiting Protein Tyrosine Kinase-7 Mediated β-Catenin Signaling. PubMed 42248674
- Front Oncol, 2022 (senior author): Development and validation of prognostic index based on immunogenic cell death-related genes with melanoma. PubMed 36419893
- J BUON, 2016 (senior author): S-1 plus sorafenib for the treatment of advanced hepatocellular carcinoma. PubMed 28039697
- Tumour Biol, 2016 (senior author): C6 ceramide sensitizes the anti-hepatocellular carcinoma (HCC) activity by AZD-8055, a novel mTORC1/2 dual inhibitor. PubMed 26897748
- J BUON, 2016 (senior author): Metronomic S-1 chemotherapy plus transcatheter arterial chemoembolization (TACE): a promising treatment of hepatocellular carcinoma refractory to TACE. PubMed 27685913
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion